EFFECTIVE yesterday, Australian patients with relapsed refractory multiple myeloma will no longer be required to use thalidomide prior to accessing Celgene's immunomodulating agent Revlimid (lenalidomide) through the Pharmaceutical Benefits Scheme.
Structurally related to known human teratogen thalidomide, Revlimid will require authority prescription - see guildlink.com.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 02 Feb 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 02 Feb 18
